Chetan Lathia

Consigliere Generale presso BIOXCEL THERAPEUTICS, INC.

Health Technology

Consumer Services

Profilo

Chetan D.
Lathia is currently the Senior Vice President & Head-Regulatory Affairs at BioXcel Therapeutics, Inc. He previously worked as the Executive Director-Clinical Pharmacology at Alexion Pharmaceuticals, Inc. and as the VP & Head-Clinical Pharmacology at Intarcia Therapeutics, Inc. Lathia holds a doctorate degree from Virginia Commonwealth University and an undergraduate degree from L.
M.
College of Pharmacy.

Posizioni attive di Chetan Lathia

Società	Posizione	Inizio
BIOXCEL THERAPEUTICS, INC.	Consigliere Generale	-

Tutte le posizioni attive di Chetan Lathia

Precedenti posizioni note di Chetan Lathia

Società	Posizione	Fine
ALEXION PHARMACEUTICALS, INC.	Corporate Officer/Principal	-
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Chetan Lathia

Formazione di Chetan Lathia

Virginia Commonwealth University	Doctorate Degree
L. M. College of Pharmacy	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Chetan Lathia

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
BIOXCEL THERAPEUTICS, INC.	Health Technology

Aziende private	2
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Health Technology
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA.	Health Technology